Anticholesteremic Agents Market Size to Surpass US$ 17.06 Billion by 2031 | Growth Plus Reports

Newark, New Castle, USA, May 02, 2023 (GLOBE NEWSWIRE) — According to a recent Growth Plus Reports study, the anticholesteremic agents market was valued at US$ 12.52 billion in 2022. It is expected to register a revenue CAGR of 3.5% and reach US$ 17.06 billion by 2031. The study examines the drivers and prospects, important strategies, , competitive circumstances, shifting market dynamics, market size, data & forecasts, and important investment regions.

Key Takeaways:

• The increasing prevalence of high cholesterol levels will drive market revenue growth.
• Increasing adoption of sedentary lifestyles and poor dietary habits will support market revenue growth.
• North America dominates the global anticholesteremic agents market. 

Download PDF Brochure of Anticholesteremic Agents Market Size – COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.growthplusreports.com/inquiry/request-sample/anticholesteremic-agents-market/8866

                                  Anticholesteremic Agents Market Scope

Market Drivers
The increasing prevalence of cardiovascular diseases and high cholesterol levels will drive the market’s revenue growth. Furthermore, a sedentary lifestyle, unhealthy dietary habits, obesity, and age-related conditions are expected to fuel the market’s revenue growth. Apart from this, advances in drug development and delivery methods and increased R&D investment are expected to support the market’s revenue growth.

Market Segmentation
Growth Plus Reports has analyzed the global anticholesteremic agents market from three perspectives: Drug Class, Distribution Channel, and Region.

• Based on the drug class, the anticholesteremic agents market is segmented into bile acid resins, statins, PCSK9 inhibitors, and others.

• Based on the distribution channel, the anticholesteremic agents market is segmented into retail, online, and hospital pharmacies.

Regional Growth Dynamics
Based on the region, the global anticholesteremic agents market is segmented into North America, Europe, Latin America, and the Middle East & Africa. North America dominates the anticholesteremic agents market with the largest revenue share because of an aging population, advances in drug development and delivery technologies, high healthcare spending, and growing awareness of the advantages of maintaining a healthy cholesterol level and the affordability of various treatment options.

Request for Customization – https://www.growthplusreports.com/inquiry/customization/anticholesteremic-agents-market/8866

Competitive Landscape

The top companies in the global anticholesteremic agents market are:

• Regeneron Pharmaceuticals Inc.
• Sanofi S.A.
• Merck & Co., Inc.
• Amgen Inc.
• Novartis AG
• AstraZeneca Plc
• Pfizer, Inc.
• Eli Lilly and Company
• Ionis Pharmaceuticals, Inc.
• Esperion Therapeutics Inc.
• Kowa Company, Ltd. (Kowa Pharmaceutical Co. Ltd.)
• NewAmsterdam Pharma B.V.

The market for anticholesteremic agents is moderately competitive, with several multinational companies involved. Key players emphasize R&D to increase their product portfolio.

Recent Developments:

• The Cholesterol Lowering through Bempedoic Acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial’s findings were made public by Esperion in March 2023. Compared to the placebo, the research found that NEXLETOL significantly lowered the risk of hard MACE-4 and MACE-3 by 13% and 15% and also reduced the risk of heart attack and coronary revascularization by 23% and 19%.

• Novartis announced in January 2022 that the US Food and Drug Administration (FDA) had approved Leqvio (inclisiran), the only small interfering RNA (siRNA) medication to reduce low-density lipoprotein cholesterol (LDL-C) with only two doses annually following an initial dosage and one at three months.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem
   2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources
   4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2022) 
   3. Regulatory Landscape
   4. Reimbursement Sicario 
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL ANTICHOLESTEREMIC AGENTS MARKET- ANALYSIS & FORECAST, BY DRUG CLASS
   1. Bile Acid Resins
   2. Statins
   3. PCSK9 Inhibitors
   4. Others
6. GLOBAL ANTICHOLESTEREMIC AGENTS MARKET- ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
   1. Hospital Pharmacies
   2. Retail Pharmacies
   3. Online Pharmacies

ANTICHOLESTEREMIC AGENTS MARKET TOC

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8866

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse more latest healthcare reports:

Swab & Viral Transport Medium Market by Type (Transport Medium and Swab Type), Indication (Herpes Simplex Virus, Influenza Virus, and Others), End User (Hospitals, Specialty Clinics) – Global Outlook & Forecast 2023-2031

Doppler Ultrasound Market by Type (Handheld, Trolly-Based), Application (Radiology, Obstetrics and Gynecology, Cardiology, Others), End User (Hospitals, Diagnostic Centers, Others) – Global Outlook & Forecast 2023-2031

Respiratory Pathogen Testing Kits Market by Product (ELISA Kits, RT PCR Kits), Application (Respiratory Syncytial Virus Infection, Influenza Virus Infection), and End User (Hospitals, Diagnostic Centers) – Global Outlook & Forecast 2023-2031

Glucose Elevating Agents Market by Products (Glucagon, Diazoxide), Indication (Hypoglycemia, Insulinoma), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), – Global Outlook & Forecast 2023-2031

Anticholesteremic Agents Market by Drug Class (Bile Acid Resins, Statins), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.